HC Wainwright restated their buy rating on shares of Curis (NASDAQ:CRIS – Free Report) in a report published on Wednesday, Benzinga reports. They currently have a $26.00 target price on the biotechnology company’s stock. Separately, Cantor Fitzgerald restated an overweight rating on shares of Curis in a research note on Wednesday. Read Our Latest Stock […]